CellOrigin and CATUG partner to advance CAR-based immunotherapy through mRNA-LNP delivery

Basel, Switzerland, March 3, 2025 – CellOrigin Biotech, a leading Chinese biopharmaceutical company specializing in the development of genetically engineered pluripotent stem cell (iPSC)-derived immune cell therapies and in vivo engineered CAR-macrophages, has signed an agreement with CATUG, a global leader in CRO/CDMO services with expertise in mRNA technology.

The collaboration will leverage CATUG's proficiency in nucleic acid and lipid nanoparticle (LNP) technology for the genetic engineering of iPSCs and immune cells, while CellOrigin Biotech will contribute its extensive experience in in vitro and in vivo studies of immune cells to support CATUG's product development. This partnership aims to accelerate the development of innovative in vivo engineered  immune cell therapies for cancer.

"We are excited to partner with CellOrigin," said Lin Jin, co-Founder and President of CATUG. "CellOrigin's expertise in immunotherapeutics and impressive track record are unmatched" she emphasized. "Together, we aim to pioneer the next generation of chimeric antigen receptor (CAR) therapies, targeting T-cells, macrophages, and NK cells. This collaboration will not only expand our capabilities in iPSC technology but also deepen our expertise in developing CAR mRNA therapies."

Dr. Jin Zhang, Scientific Founder of CellOrigin Biotech commented on the strategic importance of the newly formed partnership, "This collaboration with CATUG represents a significant leap forward in our manufacturing capabilities and streamlining our production processes. It's a crucial step in our long-term strategy to deliver cutting-edge cell therapies to patients." He further elaborated on the potential benefits, adding, "CATUG's expertise and resources will be invaluable as we work together to develop groundbreaking allogeneic cell therapies."

CellOrigin Biotech and CATUG collaboration will focus on manufacturing and development projects, advancing CAR-based immunotherapy through mRNA-LNP delivery. The combined expertise of both companies is expected to accelerate the translation of these innovative therapies from the laboratory to the clinic, offering new hope for cancer patients. The focus on manufacturing and development underscores the commitment of both partners to bringing these life-saving therapies to market as quickly and efficiently as possible.

About CellOrigin Biotech
CellOrigin Biotech (Hangzhou) Co., Ltd. is dedicated to developing genetically engineered, pluripotent stem cell (iPSC)-derived immune cell therapies, including macrophage and NK cell therapies, as well as developing in vivo CAR-macrophage therapies for treating cancer and other complex diseases beyond cancer.

For more information, please visit https://en.cell-origin.com 

About CATUG
Headquartered in Basel, Switzerland, CATUG is known for its rapid and flexible approach to providing contract research, development, and GMP manufacturing services across the RNA therapeutic pipeline. The company specializes in the development of plasmid DNA, mRNA, siRNA, and lipid nanoparticles, and offers a wide spectrum of analytical services for sample QC.

For more information, please visit https://www.catug.bio